Clarimedix, Inc. (Boulder), a privately held company focused on the development of non-invasive therapeutics for the treatment of disorders associated with vascular dysfunction, today announced that an investment has been secured from the Johnson & Johnson Corporate Office of Science and Technology (COSAT).  Financial terms of the deal are not disclosed.  The funds secured from this investment will be used for a human proof-of-concept study to determine the viability of Clarimedix's product for cerebral vasospasm.  The study will be completed by the end of the second quarter, at which point the company anticipates closing a further round of investment from an investor syndicate.  http://www.prnewswire.com/news-releases/clarimedix-inc-secures-investment-for-proof-of-concept-study-in-cerebral-vasospasm-137094653.html

Go Back